17.00 +0.03 (0.18%)
After hours: 5:08PM EST
|Bid||16.96 x 3200|
|Ask||16.98 x 800|
|Day's Range||16.91 - 17.27|
|52 Week Range||15.95 - 39.25|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-30.03%|
|Beta (3Y Monthly)||2.15|
|Expense Ratio (net)||0.75%|
WAYV, the VC-backed company launched by Eaze’s founder Keith McCarty, and finance and compliance tech company Hypur have partnered up to launch a “credit card-like” B2B technology solution for the cannabis industry. The payments solution, aimed at the entire cannabis supply chain, helps businesses reduce their reliance on cash, move money across the supply chain digitally, and automate compliance and taxes. McCarty told Benzinga WAYV was founded to solve one the biggest problems the legal cannabis industry faces today: finances.
To help put a definitive end to persisting illicit cannabis markets, Uruguay's senate has passed a new bill to regulate medical marijuana. The bill, "A Comprehensive Law for the Promotion and Access to Medical and Therapeutic Cannabis," was introduced into Congress by the "Ir" sector of the “Frente Amplio” party, and approved unanimously. The new bill also presents guidelines for pharmaceutical compounding.
This week on the show, we dive into hot topic in the world of Hip Hop and Politics. Javier Hasse is the author of the book Start Your Own Cannabis Business (Entrepreneur Press 2018), which hit the #1 Best Seller spot on Amazon, as well as a cannabis-focused, award-winning reporter and editor, with more than 4,700 unique articles published across numerous mass media outlets.
Canopy Growth Corp. said Monday it has named David Klein, currently chief financial officer at its biggest shareholder, Constellation Brands Inc., as its new chief executive, taking over from Mark Zekulin on January 14.
DETROIT — The premier gathering of cannabis entrepreneurs and investors in North America, the Benzinga Cannabis Capital Conference , is heading to Miami in 2020 for its sixth installment. The conference, ...
Canopy Growth Corp. said Monday it has named David Klein, chief financial officer at its biggest shareholder, Constellation Brands Inc. , as its chief executive officer, effective Jan. 14. Klein will replace current CEO Mark Zekulin, who will be stepping down and resigning his board seat within a year. Canopy is the cannabis sector market leader, thanks to a $4 billion investment from Corona beer brewer Constellation last year. The company ousted Zekulin's co-CEO and Founder Bruce Linton in July, and initiated a CEO search. Canopy's U.S.-listed shares rose 1.9% premarket, but are down 31% in 2019, while the ETFMG Alternative Harvest ETF has fallen 32% and the S&P 500 has gained 25%.
On Oct. 29, the United States Department of Agriculture released its long-awaited draft regulations for hemp production. Although hemp had been officially descheduled from the Controlled Substances Act by the 2018 Farm Bill, farmers and producers were still waiting on the guidance. The crop was federally legalized in 2014, and the 2018 Bill extended a program for domestic hemp production.
The Global Alliance for Cannabis Commerce said Thursday it's starting a nationwide, voluntary industry certification that vouches for safety and purity in cannabis product testing. The program should provide the consumers and licensed sellers with the certainty of the purity and safety of the legal product, under raised state standards. The Global Alliance for Cannabis Commerce will open nominations for membership on the Standards Committee on Thursday, and end it on Jan. 30, 2020.
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...
Brazil has become the third Latin American country to regulate the sale of medical marijuana after Uruguay and Colombia. On Tuesday, ANVISA (the National Agency for Health Supervision) announced it has unanimously approved the regulation of medical marijuana to be sold at pharmacies and drugstores nationwide. Brazil is Latin America’s biggest and most-populated country, with over 210 million inhabitants.
Like many states, Maryland has a medical cannabis market that shows growth, potential and significant pain points. Maryland began revising its cannabis laws in 2012 when state lawmakers approved a medical marketplace. In 2017, Maryland's medical program became operational.
Canopy Growth Corp., the Canadian cannabis company that is the market leader thanks to a $4 billion investment from a major drinks company, will not be profitable on a per-share basis by fiscal 2022, MKM analyst Bill Kirk said Friday.
MKM analyst Bill Kirk offered 10 questions he suggests analysts attending Canopy Growth Corp.'s Dec. 3 investor meeting should ask the Canadian cannabis market leader in a note Friday in which he said profitability will remain elusive for the company. "Unlike market expectations, we do not expect Canopy to become a profitable organization by FY2022 (on EPS)," Kirk wrote in a note to clients. "Current spending is the beginning of what is needed to capture future profitable opportunities. Existing cultivation businesses will continue to be under pressure as more supply comes online." Brand differentiation in the new sector is unpredictable, he wrote, although Canopy should benefit from better R&D than peers, thanks to its $4 billion investment from Corona beer maker Constellation Brands Inc. , he wrote. The company's excessive executive compensation policy is to blame for its losses and inventory levels remain a risk if demand does not materialize or is delayed, he said. Kirk suggests investors ask about that policy and whether cuts have impacted morale. He suggests asking whether the FDA's update on CBD will affect the company's plans for CBD beverages and how much more labor the products to be released under Cannabis 2.0., the launch of derivatives in Canada, require. Kirk rates Canopy stock as neutral with a C$23 ($17) fair value stock price estimate, below it's current price of C$25.54. U.S.-listed shares were up 2.2% in premarket trade Friday, but are down 30% in 2019, while the ETFMG Alternative Harvest ETF has fallen 31% and the S&P 500 has gained 26%.
Cannabis stocks rose Wednesday to recover some of their prior-day losses, boosted by expectations for a steep rise in spending on cannabis over the Thanksgiving period, one of the busier shopping periods of the year.
Cresco Labs Inc. reported revenue Tuesday that missed Wall Street expectations. The weed producer reported a third-quarter net loss of $8.6 million, versus net income of $1.2 million in the year-ago quarter. Cresco did not report a per-share earnings figure. Revenue rose to $36.2 million from $12.7 million a year ago. Analysts polled by FactSet expected sales of $37.9 million. U.S. traded shares of Cresco Labs have dropped 14% this year, as the S&P 500 index has gained 25%. The ETFMG Alternative Harvest ETF has fallen 32% this year. Cresco shares closed up 0.7% in regular trading Tuesday.
MedMen Enterprises Inc. reported Tuesday that revenue rose 105% but the cannabis company missed Wall Street consensus sales estimates. The weed retailer reported a fiscal first-quarter net loss of $31.5 million, which amounts to 16 cents a share, versus $12.5 million, or 27 cents a share in the year-ago quarter. Revenue rose to $44 million from $21.5 million a year ago. Analysts polled by FactSet had modeled sales of $47.9 million. "We entered Fiscal 2020 on a mission to build a more nimble and financially flexible MedMen," Chief Executive Adam Bierman said in a statement. "As we right-size our organization and implement an intensified focus on free cash flow generation, our business will become more efficient, in turn allowing us to better serve our stakeholders." The company has said previously that it is laying off roughly 20% of its employee base which should achieve $10 million in annual cost savings. U.S.-traded shares of MedMen have fallen 83% this year, as the S&P 500 index gained 25%. The ETFMG Alternative Harvest ETF has fallen 32% this year.
The marijuana industry is made up of companies that either support or are engaged in the research, development, distribution, and sale of medical and recreational marijuana. The biggest companies include Canopy Growth Corp. (CGC), Tilray Inc. (TLRY), and Aurora Cannabis Inc. (ACB), but the industry has scores of upstarts that are trying to grab a piece of the market. The marijuana industry, as measured by the ETFMG Alternative Harvest ETF (MJ), has substantially underperformed the S&P 500 over the past year.
Cresco Labs said Tuesday it has terminated the acquisition of VidaCann Ltd. announced in March in a deal that would have cost it $120 million. Chicago-based Cresco Labs said the decision was made to conserve cash as it works to accelerate top and bottom-line growth. The company has also signed an agreement for a sale-and-leaseback of two properties in Ohio and Michigan that will allow it to raise $38 million in non-dilutive financing. "The team and operations at VidaCann are phenomenal, but with a focus on managing our cost of capital, and insuring the most efficient and highest return on invested capital, the ability to deploy resources to other, existing, Cresco markets that are widely considered some of the top markets in the US, like Illinois, Pennsylvania, California and Nevada, has to take priority," Chief Executive and co-Founder Charlie Bachtell said in a statement. The company is the latest to drop a planned acquisition as the cannabis sector has been hurt by the slower-than-expected development of the legal market in Canada and the U.S. U.S.-listed shares were not active premarket, but have fallen 15% in 2019, while the ETFMG Alternative Harvest ETF has fallen 31% and the S&P 500 has gained 25%.
The U.S. Food and Drug Administration said late Monday that it cannot conclude that cannabidiol, or CBD, is generally recognized as safe among experts for its use in human or animal food. Weed stocks dipped in the extended session, with Tilray Inc. falling nearly 1%, and Aurora Cannabis Inc. falling 0.4%. Canopy Growth Corp. stock was up 0.3% and Cronos Group Inc. was flat. As a part of the announcement, the FDA said it had warned 15 companies around the U.S. that they were illegally selling products containing CBD, a nonintoxicating cannabinoid found in the cannabis plant. The revised consumer update issued late Monday discusses safety concerns around CBD use and potential liver injury, as well as side effects such as drowsiness, gastrointestinal distress, and changes in mood. The FDA said it plans to continue to issue updates as it learns more about CBD. The revised consumer update included the warning that it is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement. The ETFMG Alternative Harvest ETF , which tracks a basket of weed and consumer packaged goods stocks, gained 0.1% in the extended session.
Canopy Growth Corp. said Monday it has received a Health Canada license for a beverage facility at its Smith Falls, Ontario headquarters. The new facility is already operational and will start producing cannabis-infused beverages on Monday, the company said in a statement. In all, eleven beverages will be produced at the facility in the first wave of production, with plans to add more through the year. Cannabis-infused beverages are allowed in Canada as part of Cannabis 2.0, the name being given to the introduction of derivatives products, including edibles and drinks. Canopy is the cannabis market leader, thanks to a $4 billion investment from Corona beer brewer Constellation Brands Inc. . Constellation helped the company with design and staffing and other issues in creating the new facility. Canopy's U.S.-listed shares rose 3% in premarket trade, but are down 31% in 2019, while the ETFMG Alternative Harvest ETF has fallen 30% and the S&P 500 has gained 24%.
With stocks breaking out to new highs, many investors are wondering whether this rally can last through the end of the year. TG Watkins, the Director of Stocks at Simpler Trading, thinks small caps are even breaking out which is a clear sign that this rally has legs. Even more, one particular sector he likes is cannabis, which might be getting ready to finally reverse course as The MORE Act removes the marijuana plant from the federal Controlled Substances Act.
The FDA is cracking down on the illegal sale of products containing CBD after warning 15 companies about their health claims. Yahoo Finance’s Zack Guzman, Heidi Chung and BigEyedWish Founder Ian Wishingrad discuss on YFi PM.